Warwick Smith, director general of the British Generic Manufacturers Association, has warned of increased costs and risks to the NHS due to intellectual property requirements sought by the US as part of a free trade agreement with the UK.
Any potential trade deal with the US must not put the UK’s National Health Service at risk, the British Generic Manufacturers Association has insisted.
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
Already a subscriber?
Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.
Glenmark’s advantage for its UK generic version of AstraZeneca’s Forxiga (dapagliflozin) has quickly been snuffed out, after the originator won on appeal its request for injunctive relief.
Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.
